SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Intel VP: "Historically, if we were to miss milestones... we usually just gave exemptions. Saying no is a pretty powerful tool"

“We’re already living in a world where AI is attacking AI”

“In many cases the first market should not be America”

“To get Israel to a more precise position in biotech, we need to educate our people to become better managers”

Buzz

Most popular

Daily

Weekly

1

“Other countries have air-defense systems, but Israel’s are better”: Arrow 3 lands in Germany as Israel pursues new mega deals

2

Johny Srouji weighs leaving Apple, raising stakes for the Israeli executive who built its silicon program

3

Nice puts Actimize up for sale at a $1.5-2 billion price tag

4

Israeli drone startup Heven hits $1 billion valuation in $100 million round led by IonQ

5

Check Point raises $1.75 billion, potentially eyeing AI expansion

Pharmaceuticals

20 stories about Pharmaceuticals

מימין תומר קריב ו רן נוסבאום מנהלי קרן פונטיפקס

Due to high demand for biotech, Pontifax crosses $1.3 billion funding threshold

12.10.20|Tzally Greenberg

A series of successful exits and investments see the Israeli fund balloon by 22% to hit $404 million since the start of the Covid-19 crisis

קור שולץ מנכ"ל חברת טבע תרופות 23.8.20

What’s behind the timed resurgence of lawsuits against Teva?

28.08.20|Sophie Shulman

The Israeli pharmaceutical giant was hit with three legal blows over the course of a few days

מוסף שבועי 16.4.20 פרופ' רגינה ברזילי

Hitting the Reset Button on Antibiotics

17.04.20|Viki Auslender

As the world faces the global threat of Covid-19 and the post antibiotic era, MIT researcher Regina Barzilay and her team are using AI to discover new chemical compounds for medical treatment

אסטרהזנקה חברת תרופות מטה בריטניה astrazeneca

Pharmaceutical Company AstraZeneca Launches Digital Health Program in Israel

27.11.19|Meir Orbach

Alongside funding, the program will provide Israeli startups with mentorship and training

מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Quarterly Report Meets Analyst Expectations

07.11.19|Sophie Shulman

The Israeli drugmaker’s revenues dropped 6% in the third quarter of 2019 to $4.26 billion. Debt dropped by $1.8 billion to $26.9 billion

מטה חברת טבע תרופות

Teva Overcomes One Hurdle, Many Still Ahead

23.10.19|Hezi Sternlicht

The Israeli drugmaker announced on Monday two major achievements regarding the opioid abuse lawsuits against it; but even without taking into consideration its additional legal complications, the settlements it has reached will severely strain its resources

אתר טבע כפר סבא

Teva to Close Missouri Plant, Report Says

29.08.19|Tzally Greenberg

Teva’s manufacturing plant in Israeli city Netanya is also slated for final closure in early 2020, as part of the company’s reorganization plan

קאר שולץ מנכל טבע

Rivals' Earning Reports Should Have Teva's Shareholders Worried

05.08.19|Uri Tal-Tene

Teva’s leadership will break its self-imposed silence on Wednesday, when the company publishes its second-quarter report for 2019

אתר טבע כפר סבא

Teva to Pay California $69 Million in Narcolepsy Drug Settlement

30.07.19|Hezi Sternlicht

The settlement addresses allegations that Teva paid competitors to delay the release of generic versions of Provigil for almost six years, helping Teva maintain a monopoly

מוסף שבועי 18.7.19 ד"ר שחר ברבש

Paving the Way to Alzheimer’s Cure, One Algorithm at a Time

19.07.19|Tzipi Smilovitz

Israeli scientist Shahar Barbash is making waves in the pharmaceutical world with a new approach to image analysis that has even chemistry Nobel laureate Michael Levitt on board

אורי קליד פאי תרפיוטיקס Pi Therapeutics

Pi Therapeutics Raises $19.7 Million

29.05.19|Hagar Ravet

Pi Therapeutics develops novel modulators of protein degradation for the treatment of cancer

מטה חברת טבע תרופות

Derivative Suit Sheds Light on Teva’s Disastrous Rimsa Acquisition

28.05.19|Hezi Sternlicht

Teva acquired Mexican drugmaker Rimsa in 2016, but an anonymous email sent a week after the deal’s completion led Teva to launch an internal investigation—and sue the sellers for fraud

מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Legal Troubles Could Weigh Down Teva’s Ability to Carry its Debt Covenants

16.05.19|Uri Tal-Tenne

On one hand, Teva is facing lawsuits that could end up costing it hundreds of millions of dollars; on the other hand, new profitable drugs and a cost-cutting reorganization program. Is it enough to keep its head above water?

מטה חברת טבע תרופות

Teva’s Shady Legal Past Still Weighs on the Debt-Laden Pharma Company

12.05.19|Hezi Sternlicht

On Friday, 43 states joined Connecticut in filing a lawsuit against senior Teva executives and against over a dozen former and current senior executives at leading generic drug companies, alleging all were involved in a drug price-fixing conspiracy

קרית שמונה קריית שמונה

Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI

02.05.19|Hezi Sternlicht

Teva is selling the plant following its 2017 plan to ameliorate its crippling debt by divesting non-core businesses and closing or selling many of its manufacturing plants

רפואה בריאות רפואי תרופות מחקר

Can-Fite BioPharma Receives $1 Million From CKD Pharmaceuticals as Part of Expanded Agreement

Israel-based Can-Fite expanded its distribution agreement with the South Korean company in February, and is entitled to up to $5 million more in milestones

מוסף רפואה מבחנה מבחנות תרופה תרופות בית חולים

Can-Fite BioPharma to Raise $3.2 Million in Direct Offering

The NYSE and Tel Aviv-listed company develops small molecule drugs used in the treatment of liver and inflammatory diseases and cancer

חברת ה תרופות טבע Teva

Teva Makes Headway in European Copaxone Patent Case

01.04.19|Lilach Baumer

Generic 40 mg versions of the drugmaker's blockbuster drug for multiple sclerosis have been available in Europe since late 2017, but Teva is now making strides in court

Life Science Investment Firm Pontifax Raises $170 Million Fund

22.11.18|Meir Orbach

The firm’s new fund, its sixth, will focus on credit loans to pharmaceutical companies planning to go public

מוסף ניתוח מנתחים רופא רופאים חדר ניתוח

Biotech Company Polypid Raises $15 Million

07.11.18|Lilach Baumer

Israel-based Polypid develops encapsulating drug delivery technology that enables extended and localized release in the body

Previous Articles More Articles